Immunoglobulins

Researchers recommend having a low clinical threshold for the diagnosis of Hashimoto’s encephalopathy in patients who reveal no apparent cause for their altered mental status, given the heterogenous nature of the condition’s presentation.

Patients with past medical histories of immunoglobulin E-mediated hypersensitivity reactions to metronidazole and other antimicrobial agents may receive safe and effective treatment using desensitization protocols.

Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.

Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency in adults.

A recent case report detailing multiple procedures and inconclusive biopsies underwent by a patient with unusual presentation of immunoglobulin G4-related disease before conclusive diagnosis emphasizes the importance of follow-up with patients with suspicion of systemic disease.

Subcutaneous immunotherapy-induced antibodies may serve as a potential allergen-targeted biologics candidate for the treatment of allergic asthma.

Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.

Current development efforts in IVIG are focused on new routes of administration for immunoglobulin that can overcome the limitations of intramuscular administration.

Dosing recommendations for patients requiring ECMO support are unlikely to be supported by high-quality evidence, but are usually extrapolated from the physicochemical characteristics of individual drugs in conjunction with data from pharmacokinetic studies and case reports.

Investigators establish 2 predictive models, which had excellent performance, and included 90 children.

Immunocompromised patients are particularly at risk of developing persistent and severe anemia caused by parvovirus infections.

Intravenous immunoglobulin shows promise as a treatment option for pregnant patients with SARS-CoV-2, influenza, and other respiratory viruses.

This combination improves patient outcomes of vaccine-induced thrombotic thrombocytopenia after a COVID-19 vaccination, according to the results of a case analysis.

In a case study, the symptoms associated with the rash are fatigue, migratory lower extremity joint pain, and swelling of the ankles and feet.

MIS-C is a rare complication of SARS-CoV-2 infection, which is characterized by symptoms such as fever, multiorgan involvement, and documented SARS-CoV-2 exposure.

Because there is an inflammatory component to Down syndrome regression disorder, it may potentially be reversible with immunotherapy.

Recent studies that indicated the efficacy of IVIG in patients with myelin oligodendrocyte glycoprotein antibody-associated disease used pediatric cohorts, with few evaluations of the treatment approach in adults.

New validated testing method for multiple sclerosis measures kappa immunoglobulin free light chains in cerebrospinal fluid.

Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

The risk of developing acute renal failure and septic shock were higher for individuals with necrotizing soft-tissue infections treated with immunoglobulins, investigators say.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

Immunoglobulin G is among clinical features linked to recurrence of polyps following endoscopic sinus surgery for chronic rhinosinusitis.

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

The safety of an anti-coronavirus hyperimmune intravenous immunoglobulin may be influenced by whether an individual is able to naturally generate SARS-CoV-2-neutralizing antibodies.

Investigators also found that intravenous immunoglobulins tend to be associated with increased frequency, though not significant, of serious adverse events.

Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.

Tralokinumab-ldrm is a human immunoglobulin G4 monoclonal antibody indicated for the treatment of moderate-to-severe atopic dermatitis.

Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.